Hybrid Closed-Loop for Perioperative Glycemic Control in T2DM With Parenteral Nutrition
Recruiting now · Not applicable
Conditions studied: Type 2 Diabetes
In brief
Glycemic control in surgical patients with type 2 diabetes mellitus (T2DM) receiving parenteral nutrition represents a major clinical challenge. This randomized controlled trial evaluates the comparative effectiveness and safety of hybrid closed-loop (HCL) insulin delivery versus conventional insulin pumps combined with continuous glucose monitoring (CGM) in perioperative T2DM patients requiring short-term parenteral nutrition.
Key facts
- Study ID
- NCT07121504
- Run by
- Second Xiangya Hospital of Central South University
- People needed
- 40
- Starts
- 2025-06-26
- Expected to finish
- 2026-06-01
- Last updated by the study team
- 2025-08-13
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age ≥18 years.
- Diagnosis of T2DM requiring surgical procedures (duration ≥2 hours) with anticipated short-term total parenteral nutrition (TPN) during the perioperative period (expected hospitalization >72 hours).
- Glycemic control criteria (meeting any of the following):
- ①HbA1c ≥7.5% or random plasma glucose ≥13.9 mmol/L
- Established T2DM with poor glycemic control (HbA1c ≥7.5%) despite combination therapy (≥2 oral antidiabetic drugs) ③Insulin-treated patients with suboptimal control (HbA1c ≥7.0%) after adequate dose adjustment.
- Willing to sign the informed consent form.
You may not qualify if…
- Patients with acute diabetic complications, including: diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar state (HHS), etc.
- Patients with type 1 diabetes or other specific types of diabetes.
- Patients with severe organ dysfunction, defined as:
- Cardiac function ≥Class III (NYHA classification)
- ALT/AST >3× upper limit of normal (ULN) ③ eGFR ≤30 mL/min/1.73 m²
- Hemoglobin <90 g/L ⑤ WBC count <4.0×10⁹/L or platelets <90×10⁹/L ⑥ Hemodynamic instability
- Patients with endocrine disorders affecting glucose metabolism, such as: hyperthyroidism, hypothyroidism, Cushing's syndrome, etc.
- Patients with known hypersensitivity to any drugs or materials used in the study protocol.
- Patients who have contraindications to conventional insulin pump therapy.
- Patients with dermatological conditions (e.g., skin rash, prurigo) or coagulation disorders.
- Patients with impaired consciousness or psychiatric disorders affecting decision-making capacity or communication ability.
- Patients who have other conditions deemed unsuitable for trial participation by investigators.
- Patients who suffer severe surgical complications.
Where it is running
- Department of Metabolism and Endocrinology, Second Xiangya Hospital of Centra South University, Changsha, Hunan 410011 — Changsha, Hunan, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.